You have 9 free searches left this month | for more free features.

rituximab

Showing 1 - 25 of 1,080

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Rituximab in Children With Blood Diseases

Not yet recruiting
  • Rituximab
  • +2 more
  • Rituximab
  • Rituximab (once a week)
  • (no location specified)
Apr 8, 2022

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +13 more
  • Polatuzumab Vedotin
  • +3 more
  • Scottsdale, Arizona
  • +11 more
Aug 23, 2022

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 4, 2022

Refractory Myasthenia Gravis, Rituximab Trial in Guangzhou (Rituximab)

Recruiting
  • Refractory Myasthenia Gravis
  • Rituximab
  • Rituximab
  • Guangzhou, China
    First Affiliated Hospital, Sun Yat-Sen University
Apr 26, 2022

Pharmacological Action Trial (Rituximab, Dexamethasone)

Not yet recruiting
  • Pharmacological Action
  • (no location specified)
Sep 22, 2022

Steroid-Dependent Nephrotic Syndrome Trial in Kolkata (Rituximab, Mycophenolate Mofetil)

Active, not recruiting
  • Steroid-Dependent Nephrotic Syndrome
  • Rituximab
  • Mycophenolate Mofetil
  • Kolkata, West Bengal, India
    Nilratan Sircar Medical College and Hospital
Apr 6, 2022

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

Mantle Cell Lymphoma Trial in Saint Louis (Bendamustine, Rituximab, Acalabrutinib)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Feb 2, 2022

Idiopathic Membranous Nephropathy Trial (Rituximab, Cyclophosphamide)

Not yet recruiting
  • Idiopathic Membranous Nephropathy
  • (no location specified)
Aug 22, 2022

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative Trial in Seattle (procedure, drug, biological)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 11, 2022

Non-Hodgkins Lymphoma Trial in Fort Myers, Nashville (Cyclophosphamide, Mitoxantrone, Vincristine)

Completed
  • Non-Hodgkins Lymphoma
  • Fort Myers, Florida
  • +1 more
Feb 21, 2022

DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

CNS Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Central Nervous System Lymphoma
  • Cincinnati, Ohio
  • +3 more
Sep 15, 2021

Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Indolent

Completed
  • Ann Arbor Stage III Grade 1 Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 28, 2021

Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL Trial run by the National Cancer Institute (NCI) (Rituximab, Copanlisib)

Recruiting
  • Follicular Lymphoma
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 18, 2022

Follicular Lymphoma Trial in Boston (Rituximab, Neo Vax, Pembrolizumab)

Recruiting
  • Follicular Lymphoma
  • Rituximab
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 14, 2022

Eosinophilic Granulomatosis With Polyangiitis Trial in Paris (Rituximab, Azathioprine, Placebo-rituximab)

Recruiting
  • Eosinophilic Granulomatosis With Polyangiitis
  • Rituximab
  • +3 more
  • Paris, France
    Hôpital Cochin
Feb 9, 2022

Chronic Lymphocytic Leukemia Trial in Washington, Hackensack (Venetoclax, Rituximab, Rituximab/Hyaluronidase Human)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Washington, District of Columbia
  • +1 more
Mar 14, 2022

Nephrotic Syndrome Trial in Kolkata (Rituximab, Tacrolimus)

Recruiting
  • Nephrotic Syndrome
  • Kolkata, West Bengal, India
    NRS Medical College & Hospital
Apr 6, 2022